文献速递乳腺癌

乳腺癌中生物标志物导向的放疗:一项叙述性综述

Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review.
PubMed 文献 · JAMA Oncol · 2025-01-01

本叙述性综述探讨将分子生物标志物整合到乳腺癌放疗决策中的潜力。文章区分了预后性与预测性生物标志物,介绍了Adjuvant Radiotherapy Intensification Classifier、Profile for the Omission of Local Adjuvant Radiation等基因组特征及免疫组化标志物在预测放疗获益方面的研究进展,并指出生物标志物导向的放疗可能有助于低复发风险患者省略放疗、高风险患者强化治疗,但仍需可靠的临床与分析验证。

要点

  • 分子生物标志物已常规用于乳腺癌全身治疗决策,但在放疗指导中的应用进展较慢。
  • Adjuvant Radiotherapy Intensification Classifier与Profile for the Omission of Local Adjuvant Radiation等工具在预测放疗获益方面显示出潜力。
  • 生物标志物导向的放疗可能帮助低复发风险患者省略放疗、识别可从强化治疗中获益者,但尚需可靠的临床与分析验证。

核心结论

  • 基于证据的共享决策对根据个体预测获益与风险及个人偏好优化治疗至关重要。
  • 将生物标志物导向的方法纳入乳腺癌放疗可能有助于个体化治疗,可能促进低复发风险患者省略放疗,同时识别可能从强化治疗中获益的患者。
  • 这种个体化放疗方法可能与改善临床结局和生活质量相关,并有助于乳腺癌患者的决策。
  • 生物标志物仍需可靠的临床与分析验证,以确保其用于放疗优化的可靠性和临床实用性。

研究设计与样本

  • 叙述性综述,探讨生物标志物导向的个体化放疗在乳腺癌中的潜力。

主要发现

  • 术后放疗推荐用于大多数保乳术后患者,并根据危险因素决定是否用于乳房切除术后。
  • 新出现的证据提示,基因表达特征评分低或具有特定临床病理特征的患者局部复发率可能非常低。
  • 综述强调了预后性与预测性生物标志物的区别,以及生物标志物研究中分析与临床效度的重要性。
  • 综述介绍了Adjuvant Radiotherapy Intensification Classifier和Profile for the Omission of Local Adjuvant Radiation在预测放疗获益方面的潜力。
  • 综述还讨论了基因组调整放疗剂量和肿瘤浸润淋巴细胞的作用,以及正在进行的探索生物标志物用于导管原位癌和浸润性乳腺癌放疗决策的临床试验。

临床怎么用

  • 作者认为,基于证据的共享决策对根据个体预测获益与风险及个人偏好优化治疗至关重要。
  • 作者认为,将生物标志物导向的方法纳入乳腺癌放疗可能有助于个体化治疗,可能促进低复发风险患者省略放疗,同时识别可能从强化治疗中获益的患者。
  • 作者认为,这种个体化放疗方法可能与改善临床结局和生活质量相关,并有助于乳腺癌患者的决策。

局限性

  • 生物标志物仍需可靠的临床与分析验证,以确保其用于放疗优化的可靠性和临床实用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Integration of molecular biomarker information into systemic therapy has become standard practice in breast cancer care. However, its implementation in guiding radiotherapy (RT) is slower. Although postoperative RT is recommended for most patients after breast-conserving surgery and, depending on risk factors, following mastectomy, emerging evidence has indicated that patients with low scores on gene expression signatures or selected clinical-pathological features may have very low local recurrence rates. This narrative review explored the potential of biomarker-directed personalized RT approaches, which may optimize treatment strategies and be associated with improved patient outcomes and experiences. OBSERVATIONS: Distinctions between prognostic and predictive biomarkers were highlighted, emphasizing the importance of analytical and clinical validity in biomarker-based studies. Findings from studies investigating the prognostic and predictive value of various genomic signatures and immunohistochemical markers for guiding breast RT were presented. These included the Adjuvant Radiotherapy Intensification Classifier and the Profile for the Omission of Local Adjuvant Radiation, which have shown potential in predicting RT benefits. The genomic-adjusted radiation dose and role of tumor-infiltrating lymphocytes were also discussed. Ongoing clinical trials exploring the use of biomarkers in ductal carcinoma in situ and invasive breast cancer to refine RT decision-making were illustrated. CONCLUSIONS AND RELEVANCE: The results of this narrative review suggest that evidence-based shared decision-making is crucial to optimize treatment according to the individual's predicted benefits and risks along with their personal preferences. Incorporation of biomarker-directed approaches in RT for breast cancer may hold promise for personalized treatment, potentially facilitating omission of RT for patients at low risk of recurrence, while identifying those who may benefit from intensified therapy. This personalized RT approach may be associated with improved clinical outcomes and quality of life and facilitate decision-making for people with breast cancer. However, there remains a need for robust clinical and analytical validation of biomarkers to ensure reliability and clinical utility for RT optimization.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Meattini I, Coles CE, Tramm T, et al. Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review. JAMA Oncol. 2025. PMID: 39820307. doi:10.1001/jamaoncol.2024.5780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。